
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Wood Hudson Cancer Research Laboratory, Newport, Kentucky; 2 Department of Mathematical Sciences, University of Cincinnati, Cincinnati, Ohio; 3 St. Elizabeth Medical Center, Edgewood, Kentucky; and 4 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
Purpose: The p21-activated kinase-1 (Pak-1) promotes cell motility and invasiveness. Pak-1 is activated by the Rac, Rho, and Cdc42 small GTPases in response to a variety of stimuli including ras and phosphatidylinositol 3'-kinase/AKT pathway activation. Because Pak-1 plays a central role in regulating cell motility and invasiveness, we sought to determine whether Pak-1 may be involved in the malignant progression of colorectal carcinoma.
Experimental Design: Pak-1 expression was examined by immunohistochemistry in archived tissues from normal human colons, tubular and tubulovillous adenomas, invasive adenocarcinomas (stages I-III/IV), and lymph node metastases (184 total specimens from 38 patients). Specific cytoplasmic immunostaining was evaluated for overall intensity and uniformity to derive a combined histoscore (stain intensity x percentage of epithelium stained).
Results: Pak-1 expression was increased significantly with colorectal cancer progression from normal tissue to lymph node metastases (P < 0.0001). Furthermore, Pak-1 expression was increased significantly in adenomas, invasive carcinomas, and lymph node metastases compared with normal colon (P < 0.0001). Strikingly, Pak-1 expression was significantly higher in lymph node metastases than in invasive cancers, adenomas, or normal colon (P < 0.0001). Moreover, in patients with multiple lesions representing different stages of disease, Pak-1 expression was increased specifically in the most advanced lesions.
Conclusions: This study demonstrates that Pak-1 expression is increased significantly with malignant progression of human colorectal carcinoma. These data, along with numerous functional studies demonstrating a central role for Pak-1 activity in tumor invasiveness and motility, implicate Pak-1 as an exciting target for therapy of colorectal carcinoma.
This article has been cited by other articles:
![]() |
J. R. Graff, B. W. Konicek, R. L. Lynch, C. A. Dumstorf, M. S. Dowless, A. M. McNulty, S. H. Parsons, L. H. Brail, B. M. Colligan, J. W. Koop, et al. eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Cancer Res., May 1, 2009; 69(9): 3866 - 3873. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Parsons and J. C. Adams Rac regulates the interaction of fascin with protein kinase C in cell migration J. Cell Sci., September 1, 2008; 121(17): 2805 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
X H Yang, Q L Wu, X B Yu, C X Xu, B F Ma, X M Zhang, S N Li, B T Lahn, and A P Xiang Nestin expression in different tumours and its relevance to malignant grade J. Clin. Pathol., April 1, 2008; 61(4): 467 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ayala, M. Baldassarre, G. Giacchetti, G. Caldieri, S. Tete, A. Luini, and R. Buccione Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation J. Cell Sci., February 1, 2008; 121(3): 369 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Espina, M. V. Cespedes, M. A. Garcia-Cabezas, M. T. G. del Pulgar, A. Boluda, L. G. Oroz, P. Cejas, M. Nistal, R. Mangues, and J. C. Lacal A Critical Role for Rac1 in Tumor Progression of Human Colorectal Adenocarcinoma Cells Am. J. Pathol., January 1, 2008; 172(1): 156 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Aoki, T. Yokoyama, K. Fujiwara, A. M. Tari, R. Sawaya, D. Suki, K. R. Hess, K. D. Aldape, S. Kondo, R. Kumar, et al. Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma Clin. Cancer Res., November 15, 2007; 13(22): 6603 - 6609. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. E. E. Rennefahrt, S. W. Deacon, S. A. Parker, K. Devarajan, A. Beeser, J. Chernoff, S. Knapp, B. E. Turk, and J. R. Peterson Specificity Profiling of Pak Kinases Allows Identification of Novel Phosphorylation Sites J. Biol. Chem., May 25, 2007; 282(21): 15667 - 15678. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Ching, V. Y.L. Leong, M.-F. Lee, H.-T. Xu, D.-Y. Jin, and I. O.-L. Ng P21-Activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving c-Jun NH2-Terminal Kinase Activation and Paxillin Phosphorylation Cancer Res., April 15, 2007; 67(8): 3601 - 3608. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada, M. Lopez-Lago, and F. G. Giancotti Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane J. Cell Biol., October 24, 2005; 171(2): 361 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark, C. Namgyal, T. Kawasaki, K. Kinsella, A. L. Michelini, P. C. Enzinger, et al. Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6650 - 6656. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |